A next-generation biologic designed to address disease progression while supporting neurological repair
Multiple sclerosis (MS) is a chronic disease in which the immune system attacks the brain and spinal cord.
This damage disrupts nerve signalling and can lead to progressive disability.
While existing treatments can reduce inflammatory relapses, many patients continue to experience neurological decline.
New therapies that address the underlying disease biology and support nerve repair remain an important unmet medical need.
IMX39 is a first-in-class drug candidate developed based on advances in the understanding of the biological mechanisms that drive multiple sclerosis.
Many current therapies focus primarily on suppressing inflammation. IMX39 is designed to address multiple aspects of the disease, including immune activity and damage to nerve cells.
By targeting several disease mechanisms simultaneously, IMX39 aims to provide a broader approach to modifying disease progression.
IMX39 has been evaluated in the EAE model, the most widely used preclinical model of multiple sclerosis.
In these studies, IMX39 demonstrated:
These results support the continued development of IMX39 toward human clinical trials.
IMX39 is currently in preclinical development, with work underway in manufacturing and regulatory preparation.
Subject to regulatory approvals, the company intends to progress IMX39 into early-phase clinical trials.
Following initial clinical data, Imunexus expects to pursue strategic partnerships or licensing opportunities to support later-stage development and commercialisation.
